vs
Pacira BioSciences, Inc.（PCRX）与Childrens Place, Inc.（PLCE）财务数据对比。点击上方公司名可切换其他公司
Childrens Place, Inc.的季度营收约是Pacira BioSciences, Inc.的1.9倍（$339.5M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs -1.3%，领先2.9%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -13.0%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -13.6%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Children’s Place是专业儿童服饰零售商，产品主要以旗下自有品牌发售，涵盖Gymboree、Sugar & Jade、PJ Place、Crazy 8等。目前该品牌在美国、加拿大、波多黎各共开设约525家门店，同时通过两个线上渠道以及15个国家的5家加盟合作伙伴开展销售，产品涵盖上衣、裙装、鞋履、裤装、睡衣、背包等全品类儿童服饰配件。
PCRX vs PLCE — 直观对比
营收规模更大
PLCE
是对方的1.9倍
$177.4M
营收增速更快
PCRX
高出18.0%
-13.0%
净利率更高
PCRX
高出2.9%
-1.3%
两年增速更快
PCRX
近两年复合增速
-13.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $339.5M |
| 净利润 | $2.9M | $-4.3M |
| 毛利率 | — | 33.1% |
| 营业利润率 | 3.9% | 1.1% |
| 净利率 | 1.6% | -1.3% |
| 营收同比 | 5.0% | -13.0% |
| 净利润同比 | — | -121.5% |
| 每股收益（稀释后） | $0.07 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXPLCE
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $339.5M | ||
| Q3 25 | $179.5M | $298.0M | ||
| Q2 25 | $181.1M | $242.1M | ||
| Q1 25 | $168.9M | $408.6M | ||
| Q4 24 | $187.3M | $390.2M | ||
| Q3 24 | $168.6M | $319.7M | ||
| Q2 24 | $178.0M | $267.9M |
净利润PCRXPLCE
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $5.4M | $-5.4M | ||
| Q2 25 | $-4.8M | $-34.0M | ||
| Q1 25 | $4.8M | $-8.0M | ||
| Q4 24 | — | $20.1M | ||
| Q3 24 | $-143.5M | $-32.1M | ||
| Q2 24 | $18.9M | $-37.8M |
毛利率PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 33.1% | ||
| Q3 25 | 80.9% | 34.0% | ||
| Q2 25 | 77.4% | 29.2% | ||
| Q1 25 | 79.7% | 28.5% | ||
| Q4 24 | 78.7% | 35.5% | ||
| Q3 24 | 76.9% | 35.0% | ||
| Q2 24 | 75.1% | 34.6% |
营业利润率PCRXPLCE
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 1.1% | ||
| Q3 25 | 3.5% | 1.4% | ||
| Q2 25 | 4.7% | -10.0% | ||
| Q1 25 | 1.2% | 1.7% | ||
| Q4 24 | 13.2% | 7.5% | ||
| Q3 24 | -82.8% | -6.8% | ||
| Q2 24 | 15.9% | -10.4% |
净利率PCRXPLCE
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -1.3% | ||
| Q3 25 | 3.0% | -1.8% | ||
| Q2 25 | -2.7% | -14.1% | ||
| Q1 25 | 2.8% | -2.0% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | -85.1% | -10.0% | ||
| Q2 24 | 10.6% | -14.1% |
每股收益（稀释后）PCRXPLCE
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.19 | ||
| Q3 25 | $0.12 | $-0.24 | ||
| Q2 25 | $-0.11 | $-1.57 | ||
| Q1 25 | $0.10 | $-0.60 | ||
| Q4 24 | $0.38 | $1.57 | ||
| Q3 24 | $-3.11 | $-2.51 | ||
| Q2 24 | $0.39 | $-2.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $7.3M |
| 总债务越低越好 | — | $107.4M |
| 股东权益账面价值 | $653.9M | $-8.6M |
| 总资产 | $1.2B | $762.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXPLCE
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $7.3M | ||
| Q3 25 | $246.3M | $7.8M | ||
| Q2 25 | $445.9M | $5.7M | ||
| Q1 25 | $493.6M | $5.3M | ||
| Q4 24 | $484.6M | $5.7M | ||
| Q3 24 | $453.8M | $9.6M | ||
| Q2 24 | $404.2M | $13.0M |
总债务PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $107.4M | ||
| Q3 25 | $376.7M | $107.2M | ||
| Q2 25 | $580.5M | $107.0M | ||
| Q1 25 | $583.4M | $166.0M | ||
| Q4 24 | $585.3M | $165.7M | ||
| Q3 24 | — | $165.4M | ||
| Q2 24 | — | $166.6M |
股东权益PCRXPLCE
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-8.6M | ||
| Q3 25 | $727.2M | $-4.9M | ||
| Q2 25 | $757.8M | $1.4M | ||
| Q1 25 | $798.5M | $-59.4M | ||
| Q4 24 | $778.3M | $-49.6M | ||
| Q3 24 | $749.6M | $-68.9M | ||
| Q2 24 | $879.3M | $-34.9M |
总资产PCRXPLCE
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $762.5M | ||
| Q3 25 | $1.3B | $805.1M | ||
| Q2 25 | $1.5B | $779.6M | ||
| Q1 25 | $1.6B | $747.6M | ||
| Q4 24 | $1.6B | $888.8M | ||
| Q3 24 | $1.5B | $921.4M | ||
| Q2 24 | $1.6B | $848.3M |
负债/权益比PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | 75.63× | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $6.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-3.4M |
| 自由现金流率自由现金流/营收 | — | -1.0% |
| 资本支出强度资本支出/营收 | — | 2.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $39.5M |
8季度趋势，按日历期对齐
经营现金流PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $6.2M | ||
| Q3 25 | $60.8M | $-30.5M | ||
| Q2 25 | $12.0M | $-43.0M | ||
| Q1 25 | $35.5M | $121.3M | ||
| Q4 24 | $33.1M | $-44.2M | ||
| Q3 24 | $53.9M | $-83.9M | ||
| Q2 24 | $53.2M | $-110.8M |
自由现金流PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-3.4M | ||
| Q3 25 | $57.0M | $-31.9M | ||
| Q2 25 | $9.3M | $-46.4M | ||
| Q1 25 | $26.9M | $121.2M | ||
| Q4 24 | $31.0M | $-47.7M | ||
| Q3 24 | $49.8M | $-91.7M | ||
| Q2 24 | $51.6M | $-115.5M |
自由现金流率PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -1.0% | ||
| Q3 25 | 31.7% | -10.7% | ||
| Q2 25 | 5.1% | -19.2% | ||
| Q1 25 | 15.9% | 29.7% | ||
| Q4 24 | 16.6% | -12.2% | ||
| Q3 24 | 29.6% | -28.7% | ||
| Q2 24 | 29.0% | -43.1% |
资本支出强度PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.8% | ||
| Q3 25 | 2.2% | 0.5% | ||
| Q2 25 | 1.5% | 1.4% | ||
| Q1 25 | 5.1% | 0.0% | ||
| Q4 24 | 1.1% | 0.9% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 0.9% | 1.8% |
现金转化率PCRXPLCE
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | -2.20× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PLCE
| The Childrens Place US | $307.4M | 91% |
| The Childrens Place International | $32.1M | 9% |
| Gift Cards | $1.7M | 1% |
